Keyphrases
Clinical Features
100%
Clinical Treatment
100%
Treatment Outcome
100%
Lymphoma
100%
Mantle Cell Lymphoma
100%
Limited-stage
100%
Chemotherapy
50%
Low Risk
50%
Risk Score
33%
Surgical Resection
16%
Radiotherapy
16%
Follow-up Interval
16%
Therapeutic Strategies
16%
Complete Response
16%
Overall Survival Rate
16%
Lactate Dehydrogenase
16%
Little Data
16%
Best Response
16%
Rare Diseases
16%
Complete Response Rate
16%
5-year Survival
16%
International Prognostic Index
16%
Clinical Risk
16%
Rituximab
16%
R-CHOP
16%
Relapse-free Survival
16%
Ann Arbor Staging
16%
Prognostic Features
16%
Systemic Evaluation
16%
Mantle Cell Lymphoma International Prognostic Index
16%
Bendamustine
16%
Limited State
16%
Neuroscience
Radiation Therapy
100%
Lactate Dehydrogenase
100%
Rituximab
100%
CHOP
100%
Bendamustine
100%
Medicine and Dentistry
Clinical Feature
100%
Mantle Cell Lymphoma
100%
Chemotherapy
50%
Surgery
16%
Disease
16%
Radiation Therapy
16%
Survival Rate
16%
Overall Survival
16%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
16%
Lactate Dehydrogenase
16%
International Prognostic Index
16%
Rituximab
16%
Recurrence Free Survival
16%
Rare Disease
16%
Bendamustine
16%
Mantle Cell Lymphoma International Prognostic Index
16%
Immunology and Microbiology
Lymphoma Cell
100%
Overall Survival
14%
Survival Rate
14%
Rituximab
14%
Recurrence Free Survival
14%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
14%